Literature DB >> 31722205

Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome.

Katherine A Waugh1, Paula Araya1, Ahwan Pandey2, Kimberly R Jordan3, Keith P Smith1, Ross E Granrath1, Santosh Khanal4, Eric T Butcher1, Belinda Enriquez Estrada1, Angela L Rachubinski5, Jennifer A McWilliams3, Ross Minter1, Tiana Dimasi1, Kelley L Colvin6, Dmitry Baturin7, Andrew T Pham1, Matthew D Galbraith4, Kyle W Bartsch1, Michael E Yeager6, Christopher C Porter8, Kelly D Sullivan9, Elena W Hsieh10, Joaquin M Espinosa11.   

Abstract

People with Down syndrome (DS; trisomy 21) display a different disease spectrum relative to the general population, including lower rates of solid malignancies and higher incidence of neurological and autoimmune conditions. However, the mechanisms driving this unique clinical profile await elucidation. We completed a deep mapping of the immune system in adults with DS using mass cytometry to evaluate 100 immune cell types, which revealed global immune dysregulation consistent with chronic inflammation, including key changes in the myeloid and lymphoid cell compartments. Furthermore, measurement of interferon-inducible phosphorylation events revealed widespread hypersensitivity to interferon-α in DS, with cell-type-specific variations in downstream intracellular signaling. Mechanistically, this could be explained by overexpression of the interferon receptors encoded on chromosome 21, as demonstrated by increased IFNAR1 surface expression in all immune lineages tested. These results point to interferon-driven immune dysregulation as a likely contributor to the developmental and clinical hallmarks of DS.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CyTOF; Down syndrome; JAK/STAT; autoimmunity; immune dysregulation; inflammation; interferon; mass cytometry; single cell; trisomy 21

Mesh:

Substances:

Year:  2019        PMID: 31722205      PMCID: PMC6871766          DOI: 10.1016/j.celrep.2019.10.038

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  81 in total

Review 1.  Systemic lupus erythematosus associated with Down syndrome.

Authors:  A Suwa; M Hirakata; S Satoh; T Ezaki; T Mimori; S Inada
Journal:  Clin Exp Rheumatol       Date:  2000 Sep-Oct       Impact factor: 4.473

Review 2.  Plasma-cell homing.

Authors:  Eric J Kunkel; Eugene C Butcher
Journal:  Nat Rev Immunol       Date:  2003-10       Impact factor: 53.106

3.  Intrinsic abnormalities of lymphocyte counts in children with down syndrome.

Authors:  Yvette C M de Hingh; Petrus W van der Vossen; Eugenie F A Gemen; André B Mulder; Wim C J Hop; Frank Brus; Esther de Vries
Journal:  J Pediatr       Date:  2005-12       Impact factor: 4.406

Review 4.  Monocytes in health and disease - Minireview.

Authors:  K R Karlmark; F Tacke; I R Dunay
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-06-13

5.  Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications.

Authors:  A J Anwar; J D Walker; B M Frier
Journal:  Diabet Med       Date:  1998-02       Impact factor: 4.359

Review 6.  Management of pulmonary hypertension and Down syndrome.

Authors:  P King; R Tulloh
Journal:  Int J Clin Pract Suppl       Date:  2011-12

7.  Human immunoglobulin selection associated with class switch and possible tolerogenic origins for C delta class-switched B cells.

Authors:  Nai-Ying Zheng; Kenneth Wilson; Xiaojian Wang; Angela Boston; Grant Kolar; Stephen M Jackson; Yong-Jun Liu; Virginia Pascual; J Donald Capra; Patrick C Wilson
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

8.  Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Authors:  Helen Gogas; John Ioannovich; Urania Dafni; Catherine Stavropoulou-Giokas; Konstantina Frangia; Dimosthenis Tsoutsos; Petros Panagiotou; Aristidis Polyzos; Othonas Papadopoulos; Alexandros Stratigos; Christos Markopoulos; Dimitrios Bafaloukos; Dimitrios Pectasides; George Fountzilas; John M Kirkwood
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

9.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

10.  Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons.

Authors:  Eric M Pietras; Ranjani Lakshminarasimhan; Jose-Marc Techner; Sarah Fong; Johanna Flach; Mikhail Binnewies; Emmanuelle Passegué
Journal:  J Exp Med       Date:  2014-02-03       Impact factor: 14.307

View more
  23 in total

1.  A Prevalent CXCR3+ Phenotype of Circulating Follicular Helper T Cells Indicates Humoral Dysregulation in Children with Down Syndrome.

Authors:  Giorgio Ottaviano; Jolanda Gerosa; Micaela Santini; Pasqualina De Leo; Andrea Vecchione; Tatiana Jofra; Cristiana Trimarchi; Maurizio De Pellegrin; Massimo Agosti; Alessandro Aiuti; Maddalena Marinoni; Maria Pia Cicalese; Georgia Fousteri
Journal:  J Clin Immunol       Date:  2020-01-28       Impact factor: 8.317

2.  Type-I-interferon signaling drives microglial dysfunction and senescence in human iPSC models of Down syndrome and Alzheimer's disease.

Authors:  Mengmeng Jin; Ranjie Xu; Le Wang; Mahabub Maraj Alam; Ziyuan Ma; Sining Zhu; Alessandra C Martini; Azadeh Jadali; Matteo Bernabucci; Ping Xie; Kelvin Y Kwan; Zhiping P Pang; Elizabeth Head; Ying Liu; Ronald P Hart; Peng Jiang
Journal:  Cell Stem Cell       Date:  2022-07-07       Impact factor: 25.269

3.  Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity.

Authors:  Katharina Lambert; Keagan G Moo; Azlann Arnett; Gautam Goel; Alex Hu; Kaitlin J Flynn; Cate Speake; Alice E Wiedeman; Vivian H Gersuk; Peter S Linsley; Carla J Greenbaum; S Alice Long; Rebecca Partridge; Jane H Buckner; Bernard Khor
Journal:  Sci Transl Med       Date:  2022-01-12       Impact factor: 19.319

Review 4.  Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome.

Authors:  Alessandra C Martini; Thomas J Gross; Elizabeth Head; Mark Mapstone
Journal:  Neuron       Date:  2022-04-25       Impact factor: 18.688

5.  JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome.

Authors:  Kathryn D Tuttle; Katherine A Waugh; Paula Araya; Ross Minter; David J Orlicky; Michael Ludwig; Zdenek Andrysik; Matthew A Burchill; Beth A J Tamburini; Colin Sempeck; Keith Smith; Ross Granrath; Dayna Tracy; Jessica Baxter; Joaquin M Espinosa; Kelly D Sullivan
Journal:  Cell Rep       Date:  2020-11-17       Impact factor: 9.423

6.  Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.

Authors:  Lisi Flores-Aguilar; M Florencia Iulita; Olivia Kovecses; Maria D Torres; Sarah M Levi; Yian Zhang; Manor Askenazi; Thomas Wisniewski; Jorge Busciglio; A Claudio Cuello
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

Review 7.  Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome.

Authors:  Anouchka P Laurent; Rishi S Kotecha; Sébastien Malinge
Journal:  Leukemia       Date:  2020-05-20       Impact factor: 11.528

8.  Genotoxic stress in constitutive trisomies induces autophagy and the innate immune response via the cGAS-STING pathway.

Authors:  Maria Krivega; Clara M Stiefel; Sahar Karbassi; Line L Andersen; Narendra K Chunduri; Neysan Donnelly; Andreas Pichlmair; Zuzana Storchová
Journal:  Commun Biol       Date:  2021-07-02

Review 9.  Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome.

Authors:  Tomer Illouz; Arya Biragyn; Maria Florencia Iulita; Lisi Flores-Aguilar; Mara Dierssen; Ilario De Toma; Stylianos E Antonarakis; Eugene Yu; Yann Herault; Marie-Claude Potier; Alexandra Botté; Randall Roper; Benjamin Sredni; Jacqueline London; William Mobley; Andre Strydom; Eitan Okun
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

Review 10.  Down syndrome and type I interferon: not so simple.

Authors:  Louise Malle; Dusan Bogunovic
Journal:  Curr Opin Immunol       Date:  2021-06-23       Impact factor: 7.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.